GLP-1 formulations
US6358924B1 · kind B1 · utility
175Cited by
8References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 1, 2000 |
| Grant date | Mar 19, 2002 |
| Priority date | — |
| Expiry date | Jun 1, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and formulations are presented that provide for a) the oral absorption of GLP-1 peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For example, a GLP-1/DSS complex is administered orally instead of parenterally, which is much more convenient for, and facilitates compliance with diabetic patients and persons with other GLP-1 treated conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.